Financials data is unavailable for this security.
View more
Year on year Kyorin Pharmaceutical Co Ltd grew net income 12.68% from 4.72bn to 5.32bn primarily through revenue growth (113.27bn to 119.53bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 5.53% growth in revenues contributed enough to still see net income improve.
| Gross margin | 42.87% |
|---|---|
| Net profit margin | 4.02% |
| Operating margin | 4.84% |
| Return on assets | 2.71% |
|---|---|
| Return on equity | 3.76% |
| Return on investment | 3.36% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Kyorin Pharmaceutical Co Ltd fell by 4.93bn. However, the company earned 1.52bn from its operations for a Cash Flow Margin of 1.27%. In addition the company used 3.19bn on investing activities and also paid 3.35bn in financing cash flows.
| Cash flow per share | 160.87 |
|---|---|
| Price/Cash flow per share | 10.42 |
| Book value per share | 2,263.35 |
|---|---|
| Tangible book value per share | 2,176.00 |
More ▼
Balance sheet in JPYView more
| Current ratio | 3.58 |
|---|---|
| Quick ratio | 1.74 |
| Total debt/total equity | 0.1895 |
|---|---|
| Total debt/total capital | 0.1593 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 12.51%. Additionally when measured on a five year annualized basis, dividend per share growth is below the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 3.25% |
|---|---|
| Div growth rate (5 year) | -7.06% |
| Payout ratio (TTM) | 62.75% |
| EPS growth(5 years) | -2.39 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -10.55 |
More ▼
